Publications and communications of Ferman Agirman

Anania, S., Farnir, M., Peiffer, R., Boumahd, Y., Thiry, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (17 February 2024). Identification of myoferlin as a mitochondria-associated membranes component required for calcium signaling in PDAC cell lines. Cell Communication and Signaling, 22 (1), 133. doi:10.1186/s12964-024-01514-z

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (06 February 2024). Exploring the impact of methylglyoxal stress on tumor immunity [Poster presentation]. Séminaire Télévie 2024.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (27 October 2023). Methylglyoxal stress : a novel role in tumor immunity ? [Poster presentation]. Annual Meeting of the Belgian Association for Cancer Research (BACR).

Boumahd, Y., Colin, G., Peiffer, R., Gullo, C., Agirman, F., Maloujahmoum, N., Coucke, P., Bellahcene, A., & Peulen, O. (04 September 2023). Modulation of radiosensitivity by myoferlin pharmacological targeting in human pancreatic cancer cell lines [Poster presentation]. GIGA day 2023, Liège, Belgium.

Crake, R., Gasmi, I., Dehaye, J., Lardinois, F., Peiffer, R., Maloujahmoum, N., Agirman, F., KOOPMANSCH, B., D’Haene, N., Azurmendi Senar, O., Arsenijevic, T., Lambert, F., Peulen, O., Van Laethem, J.-L., & Bellahcene, A. (17 May 2023). Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Cells, 12 (10), 1414. doi:10.3390/cells12101414

Peiffer, R., Boumahd, Y., Gullo, C., Agirman, F., Maloujahmoum, N., Masamune, A., Letellier Elisabeth, Bellahcene, A., & Peulen, O. (03 May 2023). Myoferlin, a new drug target in pancreatic CAFs, promotes desmoplasia and tumor aggressiveness [Poster presentation]. Gordon Research Conference - Pancreatic Diseases, Lucca, Italy.

Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., & Janji, B. (2023). Enhancement of anti-tumor immunity through interference with glycation stress in breast cancer [Poster presentation]. GIGA day.

Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (30 September 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Investigation of STAT3 involvement [Poster presentation]. BACR 2022, Gand, Belgium.

Mouziane, L., Crake, R., Maloujahmoum, N., Agirman, F., Roncarati, P., Herfs, M., & Bellahcene, A. (30 September 2022). Characterisation of methylglyoxal stress in human colorectal cancer and liver metastases using immunohistochemistry [Poster presentation]. BACR, Gent, Belgium.

Peiffer, R., Boumahd, Y., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Masamune Atsushi, Letellier Elisabeth, Bellahcene, A., & Peulen, O. (30 September 2022). The role of myoferlin in PDAC fibroblasts and desmoplasia [Poster presentation]. BACR - annual meeting 2022, Ghent, Belgium.

Peiffer, R., Boumahd, Y., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Asamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (06 September 2022). The role of myoferlin in pancreatic cancer fibroblasts and desmoplasia [Poster presentation]. GIGA Day 2022, Liège, Belgium.

Rademaker, G.* , Boumahd, Y.* , Peiffer, R., Anania, S., Wissocq, T., Liégeois, M., Luis, G., Sounni, N. E., Agirman, F., Maloujahmoum, N., De Tullio, P., Thiry, M., Bellahcene, A., Castronovo, V., & Peulen, O. (July 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biology, 53, 102324. doi:10.1016/j.redox.2022.102324
* These authors have contributed equally to this work.

Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (22 June 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells [Poster presentation]. EACR 2022.

Peiffer, R., Anania, S., Boumahd, Y., Agirman, F., Maloujahmoum, N., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (June 2022). The oncoprotein myoferlin as potential new participant in myCAF activity in pancreatic cancer [Poster presentation]. EACR 2022, Sevilla, Spain.

Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Investigation on the involvement of STAT3 [Paper presentation]. GIGA Day 2022, Liège, Belgium.

Gullo, C., Boumahd, Y., Peiffer, R., Anania, S., Agirman, F., Maloujahmoum, N., Thiry, M., Bellahcene, A., & Peulen, O. (2022). Myoferlin controls beta actin cytoskeleton integrity in pancreas cancer [Paper presentation]. GIGA Day 2022, Liège, Belgium.

Rademaker, G., Costanza, B., Pyr Dit Ruys, S., Peiffer, R., Agirman, F., Maloujahmoum, N., Vertommen, D., Turtoi, A., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2022). Paladin, overexpressed in colon cancer, is required for actin polymerisation and liver metastasis dissemination. Oncogenesis, 11, 42. doi:10.1038/s41389-022-00416-4
* These authors have contributed equally to this work.

Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Maloujahmoum, N., Agirman, F., Bellahcene, A., & Peulen, O. (14 December 2021). Myoferlin targeting primes ferroptosis in pancreatic cancer cells [Poster presentation]. GIGA cancer day.

Peiffer, R., Anania, S., Boumahd, Y., Agirman, F., Maloujahmoum, N., Bossicard, Y., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (December 2021). Deciphering the role of myoferlin in pancreatic stellate cells, key players in the pancreatic tumor microenvironment [Poster presentation]. GIGA-Cancer day 2021, Liège, Belgium.

Crake, R., Agirman, F., Arsenijevic, T., Maloujahmoum, N., Peulen, O., Van Laethem, J.-L., & Bellahcene, A. (14 October 2021). Improving pancreatic cancer response to gemcitabine by overcoming methylglyoxal driven suppression of AMPK [Poster presentation]. GIGA-Cancer Day, Liege, Belgium.

Anania, S., Boumahd, Y., Peiffer, R., Thiry, M., Hego, A., Maloujahmoum, N., Agirman, F., Bellahcene, A., & Peulen, O. (June 2021). Myoferlin, a promising therapeutic target in PDAC, is located in mitochondria-associated membranes [Poster presentation]. 27TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH.

Peiffer, R., Anania, S., Boumahd, Y., Agirman, F., Maloujahmoum, N., Bossicard, Y., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (June 2021). New insights on the role of myoferlin in pancreatic stellate cells, the key orchestrators of pancreatic tumor microenvironment [Poster presentation]. EACR 2021.

Anania, S., Peiffer, R., Rademaker, G., Hego, A., Thiry, M., Deldicque, L., Francaux, M., Maloujahmoum, N., Agirman, F., Bellahcene, A., Castronovo, V., & Peulen, O. (21 June 2020). Myoferlin is a yet unknown interactor of the mitochondrial dynamics’ machinery in pancreas cancer cells. Cancers, 12 (6), 1643. doi:10.3390/cancers12061643

Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., KOOPMANSCH, B., MacKay, G. M., Chiavarina, B., Costanza, B., Rademaker, G., Durieux, F., Agirman, F., Maloujahmoum, N., Cusumano, P. G., LOVINFOSSE, P., Leung, H. Y., LAMBERT, F., Bours, V., ... Bellahcene, A. (04 February 2020). Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. Cell Reports, 30 (5), 1400-1416.e6. doi:10.1016/j.celrep.2020.01.012

Anania, S., Rademaker, G., Peiffer, R., Hego, A., Deldicque, L., Maloujahmoum, N., Agirman, F., Bellahcene, A., Castronovo, V., & Peulen, O. (February 2020). Role of myoferlin in mitochondrial dynamics and metabolic fitness of pancreas cancer [Poster presentation]. BACR Annual Meeting 2020 - Cancer metastases: from bedside to bench, Brussels, Belgium.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (December 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic cancer cells by enhancing the migratory capacity through the control of oxidative phosphorylation [Poster presentation]. Cirm Annual meeting.

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (26 November 2019). Myoferlin depletion induces DNA damage response and p53- dependent cell cycle arrest and apoptosis in colon cancer [Poster presentation]. Metabolism in Cancer and Stromal Cells (2nd edition), Leuven, Belgium.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (November 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic cancer cells by enhancing the migratory capacity through the control of oxidative phosphorylation [Poster presentation]. Bioforum Uliège.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (23 October 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity Through the Control of Oxidative Phosphorylation [Poster presentation]. Pancreatic Cancer Symposium, Toulouse, France.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (13 June 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity Through the Control of Oxidative Phosphorylation [Poster presentation]. Belgian Society for Cell and Developmental Biology - Spring Meeting, Liège, Belgium.

Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Di Valentin, E., Goval, J.-J., Bellahcene, A., Castronovo, V., & Peulen, O. (June 2019). Myoferlin contributes to the metastatic phenotype of pancreatic cancer cells by enhancing their migratory capacity through the control of oxidative phosphorylation. Cancers, 11 (6). doi:10.3390/cancers11060853

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (2019). Human colon cancer overexpress myoferlin to maintain a fit mitochondrial network and escape p53 dependent apoptosis [Poster presentation]. Belgian Association for Cancer Research Congress, Anvers, Belgium.

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2019). Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis. doi:10.1038/s41389-019-0130-6
* These authors have contributed equally to this work.

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (2018). Myoferlin depletion induces DNA damage response and p53 dependent cell cycle arrest and apoptosis in colon cancer [Poster presentation]. Third Symposium of UBRC, Bruxelles, Belgium.